Background: Pembrolizumab plus chemotherapy is the standard perioperative treatment for high-risk stage II–III triple-negative breast cancer (TNBC), based on the overall survival benefit in KEYNOTE-522. In Brazil, pembrolizumab is approved but not funded by the public health system (SUS), which covers ~76% of the population. We estimated the population impact of delayed access.Materials and Methods: A nationwide counterfactual model estimated the consequences of a 10-year delay in pembrolizumab availability within SUS. The annual eligible cohort was derived from breast-cancer incidence, private-coverage data, TNBC prevalence, and the stage II–III proportion. Treatment effect used the 5-year KEYNOTE-522 update (OS 86.6% vs 81.7%; HR 0.66). Preventable deaths were computed from the absolute 5-year mortality reduction and life-years lost from restricted mean survival time, under 95%, 75%, and 50% uptake, with deterministic and probabilistic sensitivity analyses.Results: Of 73,610 annual breast-cancer cases, approximately 5,384 women were eligible within SUS. At 95% uptake, a 10-year delay was associated with 251 preventable deaths per annual cohort 2,506 preventable deaths and 5,156 life-years lost overall, corresponding totals were 1,979 deaths (75%) and 1,319 deaths (50%). Results were most sensitive to treatment effect and TNBC prevalence, and probabilistic analyses consistently supported substantial benefit.Conclusion: Delayed incorporation of perioperative pembrolizumab into SUS is expected to cause substantial avoidable deaths and life-years lost among women with high-risk early TNBC. These estimates quantify the clinical cost of delayed access and may inform health-technology-assessment and reimbursement decisions.